Natalizumab
How it works: Keeping immune cells out of the brain →
Tysabri
EU: Approved in the EU since 2006US: FDA approved 2004
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
- Targets
- Integrin alpha-4/beta-1, Integrin alpha-4/beta-7
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
- EMA referral · 2015-05-07
Tysabri Source
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
3,204 reports in total, 1,829 marked serious.
- Fatigue449
- Headache362
- Multiple sclerosis relapse194
- Multiple sclerosis180
- Asthenia165
- Nausea153
- Influenza like illness147
- Dizziness136
- Pain132
- Urinary tract infection129
Trials
Key trials
Large trials with a reported result on their main goal.
- Natalizumab, phase 3
Terminated · Phase 3 · Relapsing MS · Stopped: no effect
- Natalizumab, phase 3
Completed · Phase 3 · Relapsing MS · Main goal not met
- Natalizumab, phase 3
Terminated · Phase 3 · Relapsing and progressive · Stopped: no effect
- Natalizumab, phase 2 / phase 3
Completed · Phase 2 / Phase 3 · Relapsing MS · Main goal met
- Natalizumab, phase 3
Completed · Phase 3 · Relapsing MS · Main goal met
- Natalizumab, phase 3
Completed · Phase 3 · Relapsing MS · Main goal met
Running now
- Dimethyl fumarate
Recruiting · Relapsing MS · ongoing
- Natalizumab
Running, not recruiting · Relapsing MS · ongoing
- AttackMS
Recruiting · Phase 2 · Early (CIS/RIS) · ongoing
- Alemtuzumab
Running, not recruiting · Relapsing MS · ongoing
- Natalizumab, phase 4
Ongoing · Phase 4 · MS (type not specified)
- Natalizumab, phase 4
Ongoing · Phase 4 · MS (type not specified) · ongoing
Other trials (62)
Completed small trials, dose-finding studies and trials in other diseases.
- Natalizumab
Terminated · Relapsing MS · stopped_other
- Natalizumab, phase 4
Terminated · Phase 4 · Relapsing MS · stopped_other
- Natalizumab
Completed · Relapsing MS · result_in_paper_unread
- Natalizumab
Status unknown · MS (type not specified) · no_result_found
- Natalizumab
Completed · Relapsing MS · no_result_found
- SUPERNEXT
Status unknown · Phase 4 · Relapsing MS · result_in_paper_unread
- NEXT-MS
Moved to EU CTIS registry · Phase 4 · Relapsing MS
- Methylprednisolone, phase 4
Status unknown · Phase 4 · Relapsing MS · no_result_found
- Antelope
Completed · Phase 3 · Relapsing MS · no_result_found
- Natalizumab
Completed · MS (type not specified) · no_result_found
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error